Auryxia (Ferric Citrate) Therapy for In-Center and Home Dialysis Participants (IMPACT)
A Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Impact of Auryxia (Ferric Citrate) on Erythropoiesis-Stimulating Agent (ESA) Use, Intravenous (IV) Iron Use, Phosphate Control, and Anemia Control in Adult Participants on In-Center Hemodialysis or Home Dialysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alaska
-
Anchorage, Alaska, United States, 99515
- US Renal Care - Dimond
-
-
Arizona
-
Mesa, Arizona, United States, 85210
- US Renal Care - Mesa
-
-
Arkansas
-
Pine Bluff, Arkansas, United States, 71603
- US Renal Care - Pine Bluff
-
-
California
-
Granada Hills, California, United States, 91325
- US Renal Care - Northridge Roscoe
-
-
Georgia
-
Dalton, Georgia, United States, 30720
- US Renal Care - Dalton
-
-
Indiana
-
Shelbyville, Indiana, United States, 46176
- US Renal Care - Major Health
-
-
New Mexico
-
Gallup, New Mexico, United States, 87301
- US Renal Care - Red Rocks
-
-
Texas
-
Dallas, Texas, United States, 75231
- US Renal Care - North Dallas
-
Dallas, Texas, United States, 75237
- Dallas Renal Group
-
San Antonio, Texas, United States, 78251
- US Renal Care - Westover Hills
-
San Antonio, Texas, United States, 78202
- US Renal Care - Houston Street
-
San Antonio, Texas, United States, 78221
- US Renal Care - Palo Alto
-
San Antonio, Texas, United States, 78221
- US Renal Care - Pleasanton Rd.
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult participants greater or equal to 18 years old.
- Diagnosis of end-stage kidney disease and receiving maintenance dialysis (in-center, home hemodialysis or peritoneal dialysis) for greater or equal to 12 weeks prior to randomization.
- Most recent transferrin saturation less than or equal to 50 percent
- Most recent serum phosphate is greater or equal to 3.0 milligrams per deciliter
- Receiving treatment for greater or equal to 8 weeks prior to screening with non-Auryxia phosphate lowering therapy. No requirement for stable dosing within this time frame.
- Receiving treatment for greater or equal to 8 weeks prior to screening with erythropoiesis-stimulating agent (any dose, any type). No requirement for stable dosing within this time frame.
- Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure.
Exclusion Criteria:
- A known allergy or intolerance to Auryxia or any of its constituents.
- Hypersensitivity reaction to previous oral iron therapy.
- History of hemochromatosis or other iron overload syndrome.
- Active malignancy requiring current treatment except for non-melanoma skin cancer regardless of treatment.
- Active drug or alcohol dependence or abuse (excluding tobacco use or medicinal or recreational marijuana) within the 12 months prior to Screening or evidence of such abuse (in the opinion of the Investigator).
- Limited life expectancy (less than 6 months), (in the opinion of the Investigator).
- Scheduled organ transplant and participants on the kidney transplant wait-list who are expected to receive a transplant within 6 months of screening. Being active on transplant list is not an exclusion. Previous kidney transplant is not an exclusion.
- Unable to comply with study requirements or in the opinion of the Investigator not clinically stable to participate in the study.
- Females who are known to be pregnant or are breast-feeding during Screening or are planning to become pregnant and breastfeeding during the study period.
- Evidence of clinically active infection at the time of Screening.
- Use of an investigational medication or participation in an investigational study within 30 days prior to Screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Ferric citrate (commercially available, Auryxia)
Ferric citrate, (commercially available Auryxia), supplied as tablets for oral administration containing 1 gram ferric citrate (210 milligrams of ferric iron).
Administered orally with meals or snacks.
|
Ferric citrate is an iron-based phosphate binder for the treatment of hyperphosphatemia in subjects with dialysis-dependent chronic kidney disease (DD CKD) and for the treatment of iron deficiency anemia (IDA) in subjects with non-dialysis dependent chronic kidney disease (NDD CKD).
Other Names:
|
|
ACTIVE_COMPARATOR: Standard of care phosphate lowering therapy
Non-Auryxia phosphate-lowering therapy administered as standard of care.
|
Subjects randomized to SOC will continue their currently prescribed dose of phosphate lowering therapy which will be dosed per local standard of care to achieve community target serum phosphate goals.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups
Time Frame: Baseline period (Month -3 to Day 1) to months 4to 6 (efficacy evaluation period)
|
Difference in change from baseline period (Month -3 to Day 1) to months 4 to 6 (efficacy evaluation period) in mean dose of erythropoiesis-stimulating agent (standardized Units per month) between Auryxia and standard of care treatment groups.
|
Baseline period (Month -3 to Day 1) to months 4to 6 (efficacy evaluation period)
|
|
Difference in mean dose of intravenous iron (milligram per month) between Auryxia and standard of care treatment groups.
Time Frame: Baseline period (Month -3 to Day 1) to months 4 to6 (efficacy evaluation period)
|
Difference in change from baseline period to efficacy evaluation period in mean dose of intravenous iron (milligrams per month) between Auryxia and standard of care treatment groups.
|
Baseline period (Month -3 to Day 1) to months 4 to6 (efficacy evaluation period)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difference in hemoglobin measurements
Time Frame: Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period).
|
Difference in proportion of measurements with hemoglobin at or above 10.0 grams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.
|
Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period).
|
|
Difference in serum phosphate measurements
Time Frame: Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period)
|
Difference in proportion of measurements with serum phosphate at or below 5.5 milligrams per deciliter between Auryxia and standard of care treatment groups during efficacy evaluation period.
|
Baseline period (Month -3 to Day 1) to months 4to6 (efficacy evaluation period)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- USRC-2021-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.